Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Gregg Fonarow and Javed Butler.
Gregg Fonarow
Connection Strength
3.545
Javed Butler
  1. Cardiovascular implications of COVID-19 versus influenza infection: a review. BMC Med. 2020 12 18; 18(1):403.
    View in: PubMed
    Score: 0.230
  2. Reply: Titration of Guideline-Directed Medical Therapy Improves Patient-Centered Outcomes in Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019 09 10; 74(10):1426-1427.
    View in: PubMed
    Score: 0.210
  3. Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. JAMA Cardiol. 2018 10 01; 3(10):1011-1019.
    View in: PubMed
    Score: 0.197
  4. Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. Circ Heart Fail. 2018 09; 11(9):e005400.
    View in: PubMed
    Score: 0.196
  5. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018 07 24; 72(4):351-366.
    View in: PubMed
    Score: 0.195
  6. Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. J Am Heart Assoc. 2018 06 12; 7(12).
    View in: PubMed
    Score: 0.193
  7. Mobile health applications in cardiovascular research. Int J Cardiol. 2018 Oct 15; 269:265-271.
    View in: PubMed
    Score: 0.193
  8. Availability and Use of Shared Data From Cardiometabolic Clinical Trials. Circulation. 2018 02 27; 137(9):938-947.
    View in: PubMed
    Score: 0.185
  9. What's Next for Acute Heart Failure Research? Acad Emerg Med. 2018 Jan; 25(1):85-93.
    View in: PubMed
    Score: 0.185
  10. Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis. Circ Heart Fail. 2017 Aug; 10(8).
    View in: PubMed
    Score: 0.182
  11. Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. Am Heart J. 2017 Jul; 189:177-183.
    View in: PubMed
    Score: 0.179
  12. Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. Int J Cardiol. 2017 Mar 01; 230:301-303.
    View in: PubMed
    Score: 0.174
  13. Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Fail Rev. 2014 Mar; 19(2):135-52.
    View in: PubMed
    Score: 0.143
  14. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care. 2019 12; 42(12):2298-2306.
    View in: PubMed
    Score: 0.053
  15. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2019 11; 7(11):933-941.
    View in: PubMed
    Score: 0.053
  16. Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HF. JACC Heart Fail. 2019 07; 7(7):615-625.
    View in: PubMed
    Score: 0.052
  17. Discharge home health services referral and 30-day all-cause readmission in older adults with heart failure. Arch Med Sci. 2018 Aug; 14(5):995-1002.
    View in: PubMed
    Score: 0.049
  18. The Current Landscape of Atrial Fibrillation and Atrial Flutter Clinical Trials: A Report of 348 Studies Registered With ClinicalTrials.gov. JACC Clin Electrophysiol. 2018 07; 4(7):944-954.
    View in: PubMed
    Score: 0.048
  19. Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure. JACC Heart Fail. 2018 06; 6(6):465-473.
    View in: PubMed
    Score: 0.048
  20. Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2018 04 01; 3(4):288-297.
    View in: PubMed
    Score: 0.048
  21. Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) Registry. Circ Cardiovasc Qual Outcomes. 2018 04; 11(4):e004668.
    View in: PubMed
    Score: 0.048
  22. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018 01 16; 71(2):201-230.
    View in: PubMed
    Score: 0.047
  23. Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. Eur J Heart Fail. 2018 04; 20(4):677-686.
    View in: PubMed
    Score: 0.046
  24. Postmarketing Adverse Events Related to the CardioMEMS HF System. JAMA Cardiol. 2017 11 01; 2(11):1277-1279.
    View in: PubMed
    Score: 0.046
  25. Incorporating Patient and Caregiver Experiences Into Cardiovascular Clinical Trial Design. JAMA Cardiol. 2017 11 01; 2(11):1263-1269.
    View in: PubMed
    Score: 0.046
  26. Lessons learned in acute heart failure. Eur J Heart Fail. 2018 04; 20(4):630-641.
    View in: PubMed
    Score: 0.046
  27. Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. Eur J Heart Fail. 2018 02; 20(2):281-291.
    View in: PubMed
    Score: 0.046
  28. Contemporary Epidemiology, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results From the China Heart Failure (China-HF) Registry. J Card Fail. 2017 Dec; 23(12):868-875.
    View in: PubMed
    Score: 0.046
  29. Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2017 Oct 10; 70(15):1861-1871.
    View in: PubMed
    Score: 0.046
  30. Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. Eur J Heart Fail. 2018 02; 20(2):359-369.
    View in: PubMed
    Score: 0.046
  31. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT. Curr Heart Fail Rep. 2017 08; 14(4):217-222.
    View in: PubMed
    Score: 0.045
  32. Digoxin and 30-Day All-Cause Readmission in Long-Term Care Residents Hospitalized for Heart Failure. J Am Med Dir Assoc. 2017 Sep 01; 18(9):761-765.
    View in: PubMed
    Score: 0.045
  33. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017 08 08; 136(6):e137-e161.
    View in: PubMed
    Score: 0.045
  34. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017 08 08; 70(6):776-803.
    View in: PubMed
    Score: 0.045
  35. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2017 08; 23(8):628-651.
    View in: PubMed
    Score: 0.045
  36. Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle? Can J Cardiol. 2017 06; 33(6):768-776.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.